166 related articles for article (PubMed ID: 25735334)
1. Effect of CXCR4 and CD133 co-expression on the prognosis of patients with stage II~III colon cancer.
Li XF; Guo XG; Yang YY; Liu AY
Asian Pac J Cancer Prev; 2015; 16(3):1073-6. PubMed ID: 25735334
[TBL] [Abstract][Full Text] [Related]
2. CD 133+ and CXCR4+ colon cancer cells as a marker for lymph node metastasis.
Silinsky J; Grimes C; Driscoll T; Green H; Cordova J; Davis NK; Li L; Margolin DA
J Surg Res; 2013 Nov; 185(1):113-8. PubMed ID: 23777983
[TBL] [Abstract][Full Text] [Related]
3. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients.
Zhang SS; Han ZP; Jing YY; Tao SF; Li TJ; Wang H; Wang Y; Li R; Yang Y; Zhao X; Xu XD; Yu ED; Rui YC; Liu HJ; Zhang L; Wei LX
BMC Med; 2012 Aug; 10():85. PubMed ID: 22871210
[TBL] [Abstract][Full Text] [Related]
4. Stromal cell derived factor-1 and CXCR4 expression in colorectal cancer promote liver metastasis.
Amara S; Chaar I; Khiari M; Ounissi D; Weslati M; Boughriba R; Hmida AB; Bouraoui S
Cancer Biomark; 2015; 15(6):869-79. PubMed ID: 26406413
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of expression of CD133 and Ki-67 in gastric cancer.
Saricanbaz I; Karahacioglu E; Ekinci O; Bora H; Kilic D; Akmansu M
Asian Pac J Cancer Prev; 2014; 15(19):8215-9. PubMed ID: 25339008
[TBL] [Abstract][Full Text] [Related]
7. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
8. CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer.
Stanisavljević L; Aßmus J; Storli KE; Leh SM; Dahl O; Myklebust MP
Tumour Biol; 2016 Jun; 37(6):7441-52. PubMed ID: 26678887
[TBL] [Abstract][Full Text] [Related]
9. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
[TBL] [Abstract][Full Text] [Related]
10. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
12. Significance of CD133 expression in esophageal squamous cell carcinoma.
Okamoto H; Fujishima F; Nakamura Y; Zuguchi M; Ozawa Y; Takahashi Y; Miyata G; Kamei T; Nakano T; Taniyama Y; Teshima J; Watanabe M; Sato A; Ohuchi N; Sasano H
World J Surg Oncol; 2013 Mar; 11():51. PubMed ID: 23448401
[TBL] [Abstract][Full Text] [Related]
13. Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB.
Li CY; Li BX; Liang Y; Peng RQ; Ding Y; Xu DZ; Zhang X; Pan ZZ; Wan DS; Zeng YX; Zhu XF; Zhang XS
J Transl Med; 2009 Jul; 7():56. PubMed ID: 19583834
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.
Xi HQ; Zhao P
J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057
[TBL] [Abstract][Full Text] [Related]
15. CD133/CD166/Ki-67 triple immunofluorescence assessment for putative cancer stem cells in colon carcinoma.
Mărgaritescu C; Pirici D; Cherciu I; Bărbălan A; Cârtână T; Săftoiu A
J Gastrointestin Liver Dis; 2014 Jun; 23(2):161-70. PubMed ID: 24949608
[TBL] [Abstract][Full Text] [Related]
16. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
[TBL] [Abstract][Full Text] [Related]
17. Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker.
Schneider M; Huber J; Hadaschik B; Siegers GM; Fiebig HH; Schüler J
BMC Cancer; 2012 Mar; 12():96. PubMed ID: 22433494
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of putative cancer stem cell markers, CD133 and Nestin, in skin tumors.
Sabet MN; Rakhshan A; Erfani E; Madjd Z
Asian Pac J Cancer Prev; 2014; 15(19):8161-9. PubMed ID: 25339000
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis.
Bellizzi A; Sebastian S; Ceglia P; Centonze M; Divella R; Manzillo EF; Azzariti A; Silvestris N; Montemurro S; Caliandro C; De Luca R; Cicero G; Rizzo S; Russo A; Quaranta M; Simone G; Paradiso A
J Cell Physiol; 2013 Feb; 228(2):408-15. PubMed ID: 22740326
[TBL] [Abstract][Full Text] [Related]
20. Clinical Significance of Cancer Stem Cell Markers CD133 and CXCR4 in Osteosarcomas.
Mardani A; Gheytanchi E; Mousavie SH; Madjd Jabari Z; Shooshtarizadeh T
Asian Pac J Cancer Prev; 2020 Jan; 21(1):67-73. PubMed ID: 31983166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
